Navigation Links
Safety Recommendations Address Blood Clot Prevention for Pregnant Mothers: Physician-Patient Alliance for Health & Safety Presentation at National Perinatal Association Conference
Date:11/14/2013

CHICAGO, Nov. 14, 2013 /PRNewswire/ -- The Physician-Patient Alliance for Health & Safety today released a draft of safety recommendations targeting venous thromboembolism (commonly referred to as blood clots) for women having cesarean and vaginal delivery, and the extension of prophylaxis post discharge.

(Logo: http://photos.prnewswire.com/prnh/20131024/CG03341LOGO)

According to the CDC, the maternal death rate in the U.S. has more than doubled since 1987.

Mary D'Alton, MD, professor of obstetrics and gynecology in the Department of Obstetrics and Gynecology at Columbia University) believes that common and preventable causes of maternal death need to be addressed.

"Though research shows that certain patient populations are especially at risk for pregnancy-related deaths and complications, no woman is immune from them," she says.  "Especially in the first few days after delivery, otherwise healthy patients are at risk for hemorrhage, hypertension and pulmonary embolism. Pulmonary embolism lends itself to prevention measures that have been shown to work in other countries. Here at Columbia University Medical Center and New York-Presbyterian Hospital, we advocate the use of sequential compression devices as well as heparin for all patients undergoing cesarean delivery. The challenge before us is to reduce preventable maternal deaths and morbidity. It's absolutely vital that hospitals adopt standardized preventative and treatment measures for all pregnant women. Multiple national organizations are collaborating to achieve this goal, and it is hoped that all healthcare facilities will participate in this effort."

A draft of the VTE Safety Recommendations was presented at the annual conference of the National Perinatal Association conference which took place November 7-9, 2014.

Michael Wong, JD, founder and executive director of the Physician-Patient Alliance, says that the presentation was made to encourage comments and responses from healthcare professionals involved with caring for the health and well-being of mothers and infants:

"The positive reception by healthcare professionals that work closely to improve the health and well-being of mothers and infants was very encouraging," says Mr. Wong.

For a copy of the draft handout, please click here. Please note that this is a draft and does not represent a final product, and should not be taken to necessarily represent the final opinion of the VTE panel assembled by PPAHS.

About PPAHS
The Physician-Patient Alliance for Health & Safety (PPAHS) is an advocacy group devoted to improving patient health and safety. PPAHS supporters include physicians, patients, individuals, and organizations. For more information can be found at www.ppahs.org

PPAHS recently released a concise checklist that reminds caregivers of the essential steps needed to be taken to initiate Patient-Controlled Analgesia (PCA) with a patient and to continue to assess that patient's use of PCA. For a free download of the PCA safety checklist, please visit http://www.ppahs.org

PPAHS is also developing safety recommendations targeting venous thromboembolism (commonly referred to as blood clots) for women having cesarean and vaginal delivery, and the extension of prophylaxis post discharge; for more on this initiative, please see http://ppahs.org/2013/05/02/preventing-death-following-cesarean-delivery/


'/>"/>
SOURCE Physician-Patient Alliance for Health & Safety (PPAHS)
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Amgen Presents Final Results from the Largest Phase 3 Open-Label Study Assessing the Safety and Efficacy of Nplate® (Romiplostim)
2. New measuring techniques can improve efficiency, safety of nanoparticles
3. Interim Clinical Trial Results Confirm Safety of Renadyl™, a Probiotic Dietary Supplement for the Support of Healthy Kidney Function
4. Targeted antibacterial agent rapidly created in response to serious food safety pathogen
5. Notre Dame paper examines nanotechnology-related safety and ethics problem
6. New Revolutionary Femoral Access Site Closure Device Shows Unparalleled Efficacy, Safety & Ease of Use, in a Wide Range of Patients Including Patients With a Challenging Anatomy
7. Alliance for Safe Biologic Medicines Chairman Urges FDA to Ensure that Patient Safety is the Cornerstone of Biosimilar Pathway
8. OrbusNeichs Combo Dual Therapy Stent™ Demonstrates Favorable Clinical and Safety Outcomes at 12-Month Follow-Up
9. Sangart Raises Additional $50M Series G Funding Following Interim Safety Analysis Of Phase 2b Study Of MP4OX In Severe Trauma Patients With Hemorrhagic Shock
10. New Epidemiological Data Provide Additional Safety Evidence for Lantus®
11. Produce Safety Researchers Awarded by ABC Research Laboratories
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/16/2017)... Feb. 16, 2017  ArmaGen, Inc., a privately ... to treat severe neurological disorders, today reported preliminary ... AGT-181, the company,s investigational therapy for the treatment ... mucopolysaccharidosis type I, or MPS I). The initial ... study, presented today at the 13 th ...
(Date:2/16/2017)...   Biostage, Inc. (Nasdaq: BSTG ... bioengineered organ implants to treat cancers and other life-threatening ... the closing on February 15, 2017 of its previously ... and warrants to purchase 20,000,000 shares of common stock, ... was priced at $0.40 per share of common stock, ...
(Date:2/16/2017)...  Dermata Therapeutics, LLC, a biotechnology company developing ... of dermatological diseases, today announced it has completed ... into a $5 million credit facility with Silicon ... capital for general corporate purposes to further Dermata,s ... of serious diseases treated by dermatologists.   ...
(Date:2/16/2017)... 16, 2017  Windtree Therapeutics, Inc. (Nasdaq: ... developing aerosolized KL4 surfactant therapies for respiratory diseases, ... study showed that aerosolized KL4 surfactant reduced lung ... preclinical animal model. The Company believes that these ... evidence that supports the role of KL4 surfactant ...
Breaking Biology Technology:
(Date:1/19/2017)... 19, 2017 According to a new report published by ... - 2022," the global biometric sensor market is expected to garner $1.5 billion ... 2015, Asia-Pacific dominated the global market and contributed over ... Continue Reading ... ...
(Date:1/18/2017)... , Jan. 18, 2017  In vitro diagnostic ... to mergers and acquisitions (M&A), and Kalorama Information expects ... such acquisitions have been shifting. Generally, uncertainty in reimbursement ... and the U.S. has changed the acquisitions landscape. Instead ... resulted in companies buying partners outside of their home ...
(Date:1/13/2017)... 13, 2017 Sandata Technologies, LLC, a ... homecare industry, including Electronic Visit Verification™ (EVV™), announced ... Jugs, as Senior Vice President of Product Management. ... of homecare experience to Sandata, where he will ... to align Sandata,s suite of solutions with the ...
Breaking Biology News(10 mins):